HTR1A: A Potential Drug Target for Alzheimer's (G3350)

Target Name: HTR1A

NCBI ID: G3350

HTR1A

HTR1A: A Potential Drug Target for Alzheimer's

HTR1A, also known as ADRBRL1, is a gene that encodes a protein located in the brain that is involved in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key regulator of the tau protein, which is a hallmark protein found in the brains of people with Alzheimer's disease.

Research has shown that individuals with certain genetic variations in the HTR1A gene are at an increased risk of developing Alzheimer's disease. These genetic variations are associated with reduced levels of the tau protein in the brain, which can lead to the formation of beta-amyloid plaques, a hallmark hallmark of Alzheimer's disease.

In addition to its role in the development of Alzheimer's disease, HTR1A has also been shown to play a key role in the regulation of normal brain function. Studies have shown that HTR1A is involved in the formation of new neurons in the brain, and that it plays a role in the regulation of the movement and behavior of those neurons.

Because of its involvement in the development and progression of Alzheimer's disease, as well as its role in the regulation of normal brain function, HTR1A is a promising drug target for the development of new treatments for this debilitating disease. Researchers are currently working to identify small molecules that can modulate the activity of HTR1A and prevent the formation of beta-amyloid plaques in the brain. These small molecules may also be used to treat individuals with Alzheimer's disease by modulating the activity of HTR1A and improving the levels of tau protein in the brain.

In conclusion, HTR1A is a gene that has the potential to be a drug target for the development of new treatments for Alzheimer's disease. Its involvement in the development and progression of this debilitating disease, as well as its role in the regulation of normal brain function, make it an attractive target for researchers to investigate further. Further studies are needed to identify small molecules that can modulate the activity of HTR1A and prevent the formation of beta-amyloid plaques in the brain. These small molecules may also be used to treat individuals with Alzheimer's disease by modulating the activity of HTR1A and improving the levels of tau protein in the brain.

Protein Name: 5-hydroxytryptamine Receptor 1A

Functions: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli

The "HTR1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HTR1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets